Dihexa: The Truth About the Most Potent Synaptogenic Peptide

#Dihexa is the most potent synaptogenic compound in research — 10 million times more potent than #bdnf at inducing new #synapse formation in cell culture assays — and has zero human clinical trials. This is the complete honest breakdown of what that number actually means, how the compound works, what the preclinical evidence shows, and the c-Met oncogene concern that almost no Dihexa content addresses.

Dihexa (PNB-0408; N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a synthetic hexapeptide derived from angiotensin IV, developed by Dr. Joseph Harding's laboratory at Washington State University with ADDF funding. It is orally bioavailable and blood-brain barrier penetrant — unusual properties for a peptide. Its mechanism: Dihexa binds HGF (hepatocyte growth factor) and potentiates its activity at the c-Met receptor on hippocampal neurons, activating PI3K/Akt and MAPK/ERK cascades that drive dendritic spine formation, synaptogenesis, and spine maturation. The 2013 landmark paper showed Dihexa reversed spatial learning deficits in scopolamine-impaired and aged rats — outperforming donepezil in aged rat models — but did not improve cognition in normal rats, implying the mechanism restores compromised function rather than enhancing healthy baseline. c-Met is a recognized proto-oncogene; the cancer concern is real and addressed in the episode.

In this video — Part 22 of the Performance Peptides Series — I cover the complete picture:
→ What Dihexa is: angiotensin IV analog, oral bioavailability, BBB penetrance, the engineering that made it pharmacologically viable
→ Discovery: Harding/WSU, ADDF funding, the AT4/IRAP mechanism correction, HGF/c-Met identification, M3 Biotechnology/Athira Pharma spinout, ATH-1017 Phase 2 trials
→ How it works: HGF potentiation (not c-Met agonism), PI3K/Akt + MAPK/ERK, dendritic spinogenesis and synaptogenesis, the precise meaning of the BDNF potency comparison
→ What the research shows: scopolamine rat model, aged rat Alzheimer's model, donepezil comparison, the critical normal cognition finding, ATH-1017 clinical data as nearest human proxy
→ The c-Met oncogene question: why it matters, the patent argument, what short-duration animal studies don't answer, ATH-1017 trial exclusion criteria, practical guidance for cancer history
→ Honest assessment: what's genuinely compelling, zero human Dihexa trials, dose extrapolation from animals, supplier quality concerns at extreme potency, the SLU-PP-332 parallel
→ Regulatory status: not FDA approved, no IND, not controlled, not WADA prohibited

This is Part 22 of the Performance Peptides Series. Watch the full series:
→ Part 1 — BPC-157: https://youtu.be/o7LlJgi38Yc?si=4ne70VY83374Ueea
→ Part 2 — TB-500: https://youtu.be/sWp4g5vr0KA?si=xxvzXg23wZi_8Z-0
→ Part 3 — GHK-Cu: https://youtu.be/phB5nMx3_jE
→ Part 4 — KPV: https://youtu.be/idvGmSamVpU
→ Part 5 — NAD+: https://youtu.be/kTA963cRrnM
→ Part 6 — SS-31 / Elamipretide: https://youtu.be/caPbe9FyLps
→ Part 7 — CJC-1295 + Ipamorelin: https://youtu.be/DfAmJq85Lk8
→ Part 8 — Tesamorelin: https://youtu.be/FbywNMarOkM
→ Part 9 — AOD-9604: https://youtu.be/qfCATN0L5Xg
→ Part 10 — SLU-PP-332: https://youtu.be/OnDJGC0KdE0
→ Part 11 — MOTS-c: https://youtu.be/1wEixzb9Z1c
→ Part 12 — Methylene Blue: https://youtu.be/6qV6aOWgpyU
→ Part 13 — DSIP: https://youtu.be/W_fgqcQ44tI
→ Part 14 — Selank: https://youtu.be/kX2O_Bwu1p4
→ Part 15 — Semax: https://youtu.be/tbPjlpLlhGo
→ Part 16 — Cardarine: https://youtu.be/u-16WOftCEs
→ Part 17 — GLP-1s: https://youtu.be/MxxTIRS7kME
→ Part 18 — Insulin: https://youtu.be/9g3EjBoW0ho
→ Part 19 — Epithalon: https://youtu.be/xUrRDNVSygs
→ Part 20 — PT-141: https://youtu.be/NVOuepnhO9M
→ Part 21 — Kisspeptin: https://youtu.be/Nr5gBXhqSZ8

→ Apply for executive performance coaching: go.wrightlifeandfit.com/optimize

─── ABOUT WRIGHT LIFESTYLE AND FITNESS ───
Wright Lifestyle and Fitness is a performance coaching practice built for high-performing male executives, business owners, and professionals over 40. Our approach is built around sustainable fat loss, strength, and energy optimization — without extreme diets or excessive gym time.

Founder Justin Wright works with CEOs, SVPs, wealth managers, and senior leaders to build precision performance systems using proprietary frameworks including the Performance Optimization Matrix™, Adaptive Training Systems, and Metabolic Precision Nutrition.

─── DISCLAIMER ───
This video is for educational purposes only and does not constitute medical advice. Dihexa is not FDA-approved and no human clinical trials have been completed. c-Met is a recognized proto-oncogene — anyone with a history of cancer or significant cancer risk factors must consult their oncologist before considering any compound activating the HGF/c-Met pathway. Only verified pharmaceutical-grade research compounds should be used. Always consult a qualified healthcare provider. Information is accurate as of April 2026.

#Nootropic

Видео Dihexa: The Truth About the Most Potent Synaptogenic Peptide канала Wright Lifestyle and Fitness